Psychopharmacology in Long QT Syndrome

← Back to Chapters

Most discussions of QT and psychiatry ask "does this drug prolong the QT?" This chapter asks a different, harder question that comes up whenever a cardiologist's note or a screening ECG lands in the chart: the patient already has a long QT — congenital long QT syndrome, or an acquired baseline prolongation — and still needs treatment for depression, psychosis, agitation, or a substance use disorder. Here the drug is not the whole story; it is one input added to a substrate that is already close to the edge. Prescribing well means understanding that additive-risk model, knowing which psychotropics sit where on the risk ladder, aggressively controlling the modifiable amplifiers, and choosing the genuinely low-risk agents that let you treat the psychiatric illness without courting torsades de pointes. For the general EKG primer, ion-channel physiology, and routine drug-induced monitoring, see the companion chapter EKG Findings in Psychiatric Practice; this chapter is about the at-risk patient specifically.

Who this chapter is about

Two overlapping groups arrive at the psychiatrist already carrying QT risk.

Congenital long QT syndrome (LQTS) is an inherited channelopathy, usually diagnosed by cardiology, in which repolarization is genetically impaired. The three common subtypes are worth knowing because their triggers differ. LQT1 (loss-of-function in the KCNQ1/I_Ks potassium channel) is the exercise- and swimming-triggered form. LQT2 (KCNH2/hERG, the I_Kr potassium channel) is triggered by emotional arousal and sudden auditory stimuli and has a recognized postpartum vulnerability — and it is mechanistically the most important subtype for us, because hERG/I_Kr is the very channel that most QT-prolonging drugs block. LQT3 (SCN5A sodium channel) causes events at rest and during sleep/bradycardia. Beta-blockade is the mainstay of management (particularly effective in LQT1 and LQT2), and avoidance of QT-prolonging drugs is a standing instruction for all of them.

Acquired baseline prolongation is the more common scenario in general psychiatry: a patient without a named syndrome whose screening or pre-treatment ECG already shows a prolonged QTc — from age, structural heart disease, prior cardiotoxic therapy, electrolyte problems, renal or hepatic disease that raises drug levels, or the cumulative effect of several drugs. Functionally, these patients occupy the same position as the congenital group: reduced repolarization reserve and little room for a drug to add more.

The mechanism in one paragraph

Ventricular repolarization depends heavily on the rapid delayed-rectifier potassium current, I_Kr, carried by the hERG channel. The great majority of QT-prolonging drugs — across psychiatry, cardiology, infectious disease and oncology — work by blocking hERG, reducing outward potassium current and lengthening the action potential. When repolarization is prolonged far enough, early afterdepolarizations can arise and trigger the polymorphic ventricular tachycardia called torsades de pointes, which may self-terminate (syncope) or degenerate into ventricular fibrillation and sudden death. In a patient whose hERG function is already reduced — genetically in LQT2, or functionally by low potassium, low magnesium, or bradycardia — the same degree of drug block produces a disproportionately larger and more dangerous effect. This is why the framing is additive, not absolute.

The additive-risk model

The single most useful mental model is that QTc on any given day is the sum of a patient's fixed substrate plus every reversible contributor stacked on top. The drug you prescribe is only one term in that sum, and often not the largest. This reframes the clinical task: rather than asking only "how many milliseconds does this drug add," ask "what is this patient's total burden, and which terms can I reduce?" A modest-risk antipsychotic given to a patient with a normal ECG, normal electrolytes, and no interacting drugs may be entirely reasonable; the same drug given to a patient with congenital LQT2, a potassium of 3.1, and a CYP inhibitor on board is not. The corollary is optimistic: because several terms are modifiable, you can frequently create enough repolarization headroom to treat the psychiatric illness safely.

Risk stratification of psychotropic medications

The tiers below reflect converging network-meta-analytic and pharmacovigilance data. They are a guide to selection in the at-risk patient, not a claim that "safe" agents are risk-free — every antipsychotic warrants attention to the modifiable amplifiers.

The modifiable amplifiers

Because the substrate is fixed but the amplifiers are not, controlling them is where most of the safety is won.

Electrolytes. Hypokalemia and hypomagnesemia both reduce repolarization reserve and are common in exactly the patients who worry us — those with eating disorders, alcohol use disorder, diuretic use, or GI losses. Repleting potassium (commonly targeted to at least 4.0 mmol/L in the high-risk patient, though newer inpatient evidence suggests 3.5 may suffice for lower-risk cases) and magnesium is a fast, high-yield intervention, and IV magnesium is the acute treatment for torsades itself.

Heart rate. Bradycardia lengthens the QT and is a particular hazard in LQT3; conversely, the beta-blockade used to protect LQTS patients is antiarrhythmic in that context even though it slows the rate — a reminder to coordinate rather than second-guess the cardiology plan.

Drug interactions. Two mechanisms compound risk. Pharmacodynamic stacking — two or more QT-prolonging drugs together (an antipsychotic plus an antiemetic like ondansetron, plus a fluoroquinolone or azole, plus methadone) — is additive. Pharmacokinetic interactions raise the level of a QT-prolonging drug by inhibiting its metabolism (for example a strong CYP2C19 inhibitor raising citalopram, or a CYP3A4 inhibitor raising a substrate antipsychotic). Renal and hepatic impairment do the same by reducing clearance — the reason this chapter's siblings on renal and hepatic impairment intersect here.

Dose and route. QT effects are dose- and concentration-dependent, so the lowest effective dose is a safety measure, not just good practice. Intravenous administration produces higher peak concentrations and carries specific torsades associations (IV haloperidol), so the route itself is a risk lever.

A practical prescribing framework

For the patient who arrives with congenital LQTS or a prolonged baseline QTc:

1. Establish the baseline. Obtain a current ECG with a properly measured QTc, know the diagnosis (congenital subtype if applicable), and review prior events and the cardiology plan.
2. Clear the reversible terms first. Check and correct potassium and magnesium, review the full medication list (prescribed, over-the-counter, and methadone) for other QT-prolonging or interacting drugs, and address bradycardia and renal/hepatic accumulation.
3. Choose from the preferred tier. Default to aripiprazole, lurasidone, brexpiprazole or cariprazine for antipsychotic needs and sertraline or a non-serotonergic option for depression; escalate to a caution-tier agent only with justification and monitoring.
4. Dose low and monitor. Use the lowest effective dose, obtain a follow-up ECG after initiation or dose increase (and at steady state for interacting regimens), and act on QTc >500 ms or a >60 ms rise from baseline by reducing dose, switching agent, or removing a stacked contributor.
5. Co-manage. Treat congenital LQTS as a shared decision with cardiology, do not stop protective beta-blockade, and document the risk-benefit reasoning when a moderate-risk agent is genuinely needed for a severe psychiatric illness.

For EKG interpretation, ion-channel detail, and routine drug-induced QT monitoring, see EKG Findings in Psychiatric Practice. This chapter completes the special-population set with renal impairment, hepatic impairment, and malabsorption & short gut.

References & Further Reading

1. Woosley RL, et al. CredibleMeds / QTdrugs List categories of risk of torsades de pointes (crediblemeds.org).
2. Beach SR, et al. QTc prolongation, torsades de pointes, and psychotropic medications. Psychosomatics.
3. Funk MC, et al. QT prolongation with antipsychotics: risk stratification and EKG monitoring. (Clinical review.)
4. US FDA Drug Safety Communication: Celexa (citalopram) dose-dependent QT prolongation and revised maximum dosing.
5. Schwartz PJ, Ackerman MJ. The long QT syndrome: a transatlantic clinical approach to diagnosis and therapy. Eur Heart J.
6. Wenzel-Seifert K, et al. QTc prolongation by psychotropic drugs and the risk of torsade de pointes. Dtsch Arztebl Int.

This chapter is an educational review for clinicians and trainees. It reflects evidence current as of September 2026 and should be validated against current product labeling, cardiology guidance, and institutional protocols; it is not a substitute for clinical judgment or cardiology co-management.